138 results on '"Rodriguez, Estelamari"'
Search Results
2. Social Determinants of Health Impact on Survival of Patients With Malignant Pleural Mesothelioma
3. The genomic, transcriptomic, and immunological profile of patients with recurrent/refractory NSCLC.
4. Physical and Psychological Impact of the Covid-19 Pandemic on Healthcare Workers, Including End of Life Care Providers
5. Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung
6. Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer
7. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
8. Supplementary Table S5 from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
9. Data from Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
10. Characterization of Incidental Pathogenic Germline Findings Detected via ctDNA among Patients with Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population
11. Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
12. Disparities in Electronic Cigarette Use: A Narrative Review
13. The Genetic Paradigm of Hereditary Breast and Ovarian Cancer in The Afro-Caribbean Population
14. Perceptions of palliative care knowledge among Hispanics in the United States: An analysis of the Health Information National Trends Survey data.
15. Therapeutic strategies in RET gene rearranged non-small cell lung cancer
16. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
17. The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
18. Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT.
19. Patterns of Immunoreactivity with TTF-1 Antibodies 8G7G3/1 and SPT24 Suggest Distinct Immunoprofiles Between Most Pulmonary and Nonpulmonary Small Cell Carcinomas.
20. Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary
21. Patterns of Immunoreactivity with TTF-1 Antibodies 8G7G3/1 and SPT24 Suggest Distinct Immunoprofiles Between Most Pulmonary and Nonpulmonary Small Cell Carcinomas
22. Abstract 1949: KRAS G12C mutations in Hispanic and non-Hispanic patients with NSCLC: clinicopathologic characteristics and prognosis
23. Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
24. PD.01.04 Rate of Pathogenic Germline Variants Detected in ctDNA Among Patients With Non-Small Cell Lung Cancer in a Predominantly Hispanic/Latinx Population
25. Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer
26. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
27. Abstract 5625: Molecular and immunologic characterization of HRAS mutations in a cohort of 6,329 patients with cutaneous melanoma
28. Abstract 48: Molecular characteristics of HRAS mutated non-small cell lung cancer (NSCLC)
29. Molecular characteristics and clinical outcomes of breast cancer with HRAS mutations.
30. Primary proximal epithelioid sarcoma of the lung successfully treated with pneumonectomy and adjuvant chemotherapy
31. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
32. Using social media and direct marketing as a platform to increase awareness of lung cancer screening in a Hispanic urban population in the post-COVID period.
33. Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy.
34. Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice.
35. Impact of COVID-19 pandemic on well-being and work-related burnout among healthcare workers at an academic center.
36. New Treatment Strategies in Patients with Advanced Non–Small-Cell Lung Cancer and Performance Status 2
37. Small Cell Lung Cancer: Past, Present, and Future
38. Abstract PS18-18: Microsatellite instability high (MSI-H) detection utilizing targeted plasma based genotyping in metastatic breast cancer
39. Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting
40. Abstract PO-256: Factors determining adherence to lung cancer screening in a Hispanic urban population
41. Outcomes of a lung cancer screening program in a Hispanic urban population: The University of Miami experience.
42. Real-world data on liquid biopsies utilization in lung cancer patients in the community setting: The Mount Sinai experience.
43. Bilateral chylous effusions as a complication of advanced chronic lymphocytic leukemia
44. Proton pump inhibitors and response to immune check-point inhibitors: Single center study.
45. Evaluating the use of prophylactic cranial irradiation in small cell lung cancer.
46. The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC) and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC).
47. The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC).
48. P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
49. Comparing survival and clinical characteristics of patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy less than and more than 2 years.
50. Assessing gender disparities in young patients with lung cancer among a diverse urban population.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.